Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3588855 | 0.91 | MTNR1A (0.50) | MTNR1AKMT2APARP1ENPP1DAO | |
| SCHEMBL31726590 | 0.85 | PARP1 (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL13663043 | 0.85 | PARP1 (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL2127227 | 0.84 | MTNR1A (0.62) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL7824667 | 0.81 | MTNR1A (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL28922916 | 0.81 | MTNR1A (0.59) | MTNR1AKMT2APARP1ENPP1DAO | |
| SCHEMBL28184833 | 0.81 | MTNR1A (0.58) | MTNR1APARP1DAOSLC22A12CYP2C19 | |
| SCHEMBL15491685 | 0.79 | MTNR1A (0.53) | MTNR1APARP1DAOSLC22A12SLC22A6 | |
| SCHEMBL15485039 | 0.79 | MTNR1A (0.53) | MTNR1AKMT2APARP1SLC22A12 | |
| SCHEMBL16195505 | 0.79 | MTNR1A (0.55) | MTNR1APARP1ENPP1DAOSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| EP-2768822-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9266876-B2 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-25 | — | — | US | disclosed |
| EP-2424840-A1 | CXCR3 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126811-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | MTNR1A 247/4885KMT2A 4544/4885PARP1 3557/4885 |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | MTNR1A 319/4885KMT2A 4032/4885PARP1 769/4885 |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | CXCR3, CXCR1, CXCR2 | MTNR1A 223/4885KMT2A 3352/4885PARP1 470/4885 |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | MTNR1A 247/4885KMT2A 4544/4885PARP1 3557/4885 |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3A, PDE4B | MTNR1A 2080/4885KMT2A 3452/4885PARP1 351/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | MTNR1A 583/4885KMT2A 3866/4885PARP1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.